Physician profile
Patrick L Godwin
NPI 1164483483
$3,169.95
in general payments reported to CMS, 2019-2025
39 companies · $648 in 2025
The $648 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $310 · 2021: $352 · 2022: $386 · 2023: $569 · 2024: $571 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,788.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $424.21 | 2021-2025 | |
| Novo Nordisk INC | $410.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $264.80 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $216.39 | 2021-2025 | Rexulti |
| Pfizer INC. | $209.45 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.21 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $149.70 | 2019-2025 | Vaxelis, Gardasil 9, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $133.07 | 2019-2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $132.64 | 2019-2024 | Farxiga, Airsupra |
| Amgen INC. | $117.33 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Janssen Pharmaceuticals, INC | $113.32 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $79.80 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.14 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.86 | 2024-2025 | |
| Corcept Therapeutics | $50.01 | 2025 | Korlym |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Godwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.